{"id":"bictegravir-emtricitabine-and-tenofovir-alafenamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abnormal liver function tests"},{"rate":null,"effect":"Renal impairment (with tenofovir component)"}]},"_chembl":null,"_dailymed":{"setId":"664cb8f0-1f65-441b-b0d9-ba3d798be309","title":"BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE) TABLET [GILEAD SCIENCES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bictegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating into host cell DNA. Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting viral RNA into DNA. Together, these three agents target multiple steps of the HIV replication cycle to suppress viral load.","oneSentence":"This combination inhibits HIV reverse transcriptase and integrase to block viral replication and prevent the integration of viral DNA into the host genome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:28.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection as a complete regimen for antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT07498153","phase":"NA","title":"Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-09-30","conditions":"Syphilis, HIV Infections","enrollment":149},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT07476339","phase":"PHASE4","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks","status":"NOT_YET_RECRUITING","sponsor":"CAN Community Health","startDate":"2026-03-23","conditions":"HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV","enrollment":200},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07055451","phase":"PHASE1","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-08-12","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT04564547","phase":"PHASE2","title":"Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-09","conditions":"HIV-1 Infection","enrollment":161},{"nctId":"NCT06544733","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-20","conditions":"HIV-1-Infection","enrollment":675},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06613685","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-21","conditions":"HIV-1-infection","enrollment":675},{"nctId":"NCT05719441","phase":"PHASE2","title":"A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-08-19","conditions":"Acute HIV Infection","enrollment":48},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT06630286","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-09","conditions":"HIV-1-infection","enrollment":609},{"nctId":"NCT06333808","phase":"PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-25","conditions":"HIV-1-infection","enrollment":577},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT06891066","phase":"PHASE2","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-14","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":150},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT07138144","phase":"PHASE4","title":"Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-07-12","conditions":"HIV Infections","enrollment":156},{"nctId":"NCT07122557","phase":"","title":"Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073","status":"NOT_YET_RECRUITING","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2025-09","conditions":"HIV-1, Public Universal Healthcare Insurance Coverage, BIC/FTC/TAF","enrollment":320},{"nctId":"NCT04530630","phase":"PHASE4","title":"Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-09","conditions":"HIV Infections, Renal Transplant Rejection","enrollment":20},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT05549180","phase":"PHASE4","title":"Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT04884139","phase":"PHASE4","title":"DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":554},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT07004933","phase":"","title":"Rapid Antiretroviral Treatment Initiation With BIC/FTC/TAF in HIV-infected People Who Inject Drugs (PWID)","status":"COMPLETED","sponsor":"Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases","startDate":"2021-12-22","conditions":"HIV Positive People Who Inject Drugs","enrollment":37},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT06374758","phase":"PHASE4","title":"Accelerated ART Initiation for PWHIV Who Are Out of Care","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-04-29","conditions":"HIV Infections, ART, Noncompliance, Patient","enrollment":120},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT04519970","phase":"NA","title":"Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)","status":"COMPLETED","sponsor":"Gregory Huhn","startDate":"2020-09-03","conditions":"Hiv","enrollment":100},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT05602506","phase":"PHASE4","title":"Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-11-15","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT06829082","phase":"","title":"Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia","status":"COMPLETED","sponsor":"Servicios de Salud IPS Suramericana S.A.S","startDate":"2024-11-15","conditions":"HIV Treatment","enrollment":161},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT06773754","phase":"NA","title":"Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per Week","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-06-14","conditions":"Virally Suppressed People With HIV","enrollment":60},{"nctId":"NCT04650269","phase":"PHASE4","title":"Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-03-04","conditions":"Harm Reduction, HIV Infections, Drug Use","enrollment":27},{"nctId":"NCT03986697","phase":"PHASE4","title":"How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: a Serial CT Study","status":"WITHDRAWN","sponsor":"University of Liverpool","startDate":"2020-02-04","conditions":"Coronary Artery Disease, Hiv","enrollment":""},{"nctId":"NCT04950530","phase":"PHASE1","title":"The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-12-22","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT06717581","phase":"","title":"Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older.","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-10-11","conditions":"HIV Infections, Drug Interaction, Elderly Infection","enrollment":50},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT04143594","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-11-22","conditions":"HIV-1-infection","enrollment":183},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT05592613","phase":"PHASE3","title":"Next Generation Ingestible Sensors for Medication Adherence Measurement","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-02-06","conditions":"HIV Infection, Adherence, Medication, Adherence, Treatment","enrollment":15},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT06465862","phase":"NA","title":"Development of a Silica Microparticle Taggant System to Measure ART Adherence","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-09-15","conditions":"Hiv, Medication Adherence, Compliance, Medication","enrollment":15},{"nctId":"NCT06356194","phase":"PHASE1","title":"Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2024-04-15","conditions":"Healthy Volunteer Study","enrollment":28},{"nctId":"NCT06518213","phase":"","title":"Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit","status":"COMPLETED","sponsor":"University Hospital for Infectious Diseases, Croatia","startDate":"2019-05-01","conditions":"HIV Infections","enrollment":112},{"nctId":"NCT05405751","phase":"PHASE4","title":"Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2022-07-04","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT03580668","phase":"","title":"Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-11-13","conditions":"HIV-1-infection","enrollment":201},{"nctId":"NCT03960645","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-06-28","conditions":"HIV-1-infection","enrollment":62},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT05064020","phase":"","title":"Bictegravir in the Elderly Living With HIV (BICEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2020-08-01","conditions":"HIV-1-infection","enrollment":162},{"nctId":"NCT04944654","phase":"PHASE4","title":"Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-01-07","conditions":"Human Immunodeficiency Virus","enrollment":1},{"nctId":"NCT05243602","phase":"PHASE4","title":"BFTAF Elderly Switch Study","status":"COMPLETED","sponsor":"University of Nairobi","startDate":"2022-02-01","conditions":"HIV-1-infection","enrollment":520},{"nctId":"NCT06375304","phase":"PHASE4","title":"The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-05-01","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT04538040","phase":"PHASE4","title":"Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine","status":"COMPLETED","sponsor":"Quest Clinical Research","startDate":"2019-12-19","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT04553081","phase":"PHASE4","title":"2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-05-26","conditions":"HIV-1-infection","enrollment":134},{"nctId":"NCT04897243","phase":"","title":"Antiretroviral Speed Access Program","status":"UNKNOWN","sponsor":"Dr. Bertrand Lebouche","startDate":"2019-08-01","conditions":"HIV Infection","enrollment":75},{"nctId":"NCT04653194","phase":"PHASE3","title":"Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2020-09-30","conditions":"Human Immunodeficiency Virus","enrollment":36},{"nctId":"NCT05122754","phase":"PHASE4","title":"Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2021-12-08","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT04249037","phase":"PHASE4","title":"Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-12-15","conditions":"HIV/AIDS","enrollment":10},{"nctId":"NCT05463783","phase":"PHASE4","title":"Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2023-03-14","conditions":"HIV Infections, Obesity","enrollment":30},{"nctId":"NCT03797014","phase":"PHASE4","title":"B/F/TAF Switch Study for HIV-HBV Coinfection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-30","conditions":"HIV-1-infection, Hepatitis B","enrollment":28},{"nctId":"NCT04826562","phase":"PHASE4","title":"Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)","status":"UNKNOWN","sponsor":"Saint Michael's Medical Center","startDate":"2021-09-26","conditions":"Human Immunodeficiency Virus","enrollment":40},{"nctId":"NCT03998176","phase":"PHASE4","title":"Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2019-10-09","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT04416906","phase":"PHASE3","title":"A Test and Treat Strategy in New HIV Diagnosis.","status":"COMPLETED","sponsor":"Judit Pich Martínez","startDate":"2020-10-05","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT04993872","phase":"PHASE4","title":"Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2022-09-29","conditions":"HIV-infected Patient Kidney Transplant Recipient","enrollment":5},{"nctId":"NCT04860505","phase":"PHASE4","title":"Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Sexually Transmitted Diseases","enrollment":20},{"nctId":"NCT05457530","phase":"PHASE3","title":"Doravirine and Weight Gain in Antiretroviral Naive","status":"WITHDRAWN","sponsor":"Prism Health North Texas","startDate":"2022-08-01","conditions":"Body Weight Changes, Human Immunodeficiency Virus, ART","enrollment":""},{"nctId":"NCT03711253","phase":"PHASE4","title":"Empiric Treatment for Acute HIV in the ED","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2019-10-14","conditions":"Acute HIV Infection","enrollment":40},{"nctId":"NCT05648201","phase":"PHASE4","title":"Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"Hiv","enrollment":36},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT04040075","phase":"PHASE4","title":"Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy","status":"TERMINATED","sponsor":"Southampton Healthcare, Inc.","startDate":"2019-07-01","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT02800655","phase":"PHASE4","title":"Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy","status":"UNKNOWN","sponsor":"University of California, San Diego","startDate":"2016-06","conditions":"HIV","enrollment":100},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03348163","phase":"PHASE4","title":"(mo)BETTA Trial in Transwomen for Optimization of ART","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-06-06","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT05526118","phase":"","title":"Advanced HIV: Outcomes for Rapid ART","status":"UNKNOWN","sponsor":"Valley AIDS Council","startDate":"2022-08-30","conditions":"HIV-1-infection","enrollment":50},{"nctId":"NCT04222283","phase":"PHASE4","title":"Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2020-08-17","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT04009057","phase":"","title":"Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-07-09","conditions":"HIV-1-infection","enrollment":143},{"nctId":"NCT03499483","phase":"PHASE4","title":"Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2019-01-24","conditions":"HIV Prevention","enrollment":52},{"nctId":"NCT02607956","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":657},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT04039217","phase":"PHASE4","title":"Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-30","conditions":"ART, HIV","enrollment":20},{"nctId":"NCT03110380","phase":"PHASE3","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-12","conditions":"HIV-1-infection","enrollment":567}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["B/F/TAF","BIKTARVY®"],"phase":"marketed","status":"active","brandName":"Bictegravir, emtricitabine, and tenofovir alafenamide","genericName":"Bictegravir, emtricitabine, and tenofovir alafenamide","companyName":"CAN Community Health","companyId":"can-community-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase and integrase to block viral replication and prevent the integration of viral DNA into the host genome. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection as a complete regimen for antiretroviral therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}